Concomi t ant Radi ot herapy and Chemot herapy f or Earl y-
St age Nasopharyngeal Carci noma
By Skye Hongiun Cheng, Stella Y.C. Tsai, K. Lawrence Yen, James Jer-Min Jian, Nei-Min Chu, Kwan-Yee Chan, Tran-Der Tan, Jason C. Cheng, Cheng-Yee Hsieh, and Andrew T. Huang Purpose: Early-stage nasopharyngeal carcinoma (NPC) continues to carry a failure rate of 15% to 30% when treated with radiotherapy alone; the benet of concomitant radiotherapy and chemotherapy (CCRT) in early-stage NPC is unclear. The purpose of this report is to describe our efforts to improve treatment outcome in early-stage NPC after CCRT. Patients and Methods: Of 189 newly diagnosed NPC patients without evidence of distant metastases who were treated in our institution between 1990 and 1997, 44 presented with early-stage (stage I and II) disease according to the American Joint Committee on Cancer (AJCC) 1997 NPC staging system. Twelve of these patients were treated with radiotherapy alone and 32 with CCRT. Each patients head and neck area was evaluated by magnetic resonance imaging or com- puted tomography. Radiotherapy was administered at 2 Gy per fraction per day, Monday through Friday, for 35 fractions for a total dose of 70 Gy. Chemotherapy consisting of cis-diamine-dichloroplatinumand uorou- racil was delivered simultaneously with radiotherapy in weeks 1 and 6 and sequentially for two monthly cycles after radiotherapy. Results: Patients who were treated with radiotherapy alone primarily had stage I disease, whereas none of those whowere treatedwithCCRT hadstage I disease (11 of 12 patients v none of 32 patients; P .001). The locoregional control rate at 3 years for the radiotherapy group was 91.7% (median follow-up period, 34 months) and was 100% for the CCRT group (median follow-up period, 44 months) (P .10). The 3-year disease-free survival rate in the radiotherapy group was 91.7% and was 96.9% in the CCRT group (P .66). Conclusion: Our results reveal excellent prognosis of AJCC 1997 stage II NPC treated with CCRT. Stage II patients with a greater tumor burden treated with CCRT showed an equal disease-free survival, compared with stage I patients treated with radiotherapy alone. A prospective randomized trial is underway to conrm the role of CCRT in stage II NPC. J Clin Oncol 18:2040-2045. 2000 by American Society of Clinical Oncology. E ARLY-STAGE nasopharyngeal carcinoma (NPC) is usually treated with radiotherapy alone. On the basis of the American Joint Committee on Cancer (AJCC) 1997 staging system, 1 the 3-year survival rate of stage I patients treated in Turkey was 100% and was 72% for stage II patients. 2 For those patients with stage I disease who were treated in New York, the 5-year survival rate was approxi- mately 70% and was approximately 50% for stage II patients. 3 The 5-year survival rate in a Hong Kong series, based on Hos staging, 3 was 80.8% in stage I patients and 71.5% in stage II patients. 4 The 5-year local control rate for T1 and T2 patients staged on the basis of the Ho system and treated with or without sequential chemotherapy (CT) ranged from 85% to 86%. 5 Even with brachytherapy incor- porated into the treatment protocol, the 5-year disease- specic survival rate for AJCC 1992 stage I and II (equal to AJCC 1997 stage I) patients was only 85.8%, and the local control was 83%. 6,7 Concomitant radiotherapy and chemotherapy (CCRT) followed by adjuvant CT has been proved superior to radiotherapy alone in the treatment of advanced-stage NPC by a large prospective randomized trial. 8 The enhancement of local control by adjunct CT in advanced-stage NPC has also been observed in a retrospective large series in Hong Kong 5 ; however, its role in early-stage NPC is not clear. In the study presented here, we retrospectively selected early- stage NPC patients, as dened by the AJCC 1997 staging system as stage I and II patients, and observed the treatment outcome using radiotherapy alone or CCRT followed by adjuvant CT during the period between 1990 and 1997 in our institution. PATIENTS AND METHODS Between April 1990 and December 1997, 189 patients with histo- logically proven NPC and without evidence of distant metastases were given denitive radiotherapy with or without CT at the Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. All patient clinical information was collated in a comprehensive Nasopharyngeal Carci- noma Data Base prospectively. Information collected in this database consisted of (1) a general data form, which included patient demo- From the Departments of Radiation Oncology, Research, Head and Neck Surgery, Medical Oncology, and Radiology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; and Department of Medicine, Duke University Medical Center, Durham, NC. Submitted October 12, 1999; accepted January 26, 2000. Supported in part by grant no. NHRI-GT-EX89P930L from the National Health Research Institutes of Taiwan, Taipei, Taiwan. Address reprint requests to Skye H. Cheng, MD, Department of Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, 125, Lih-Der Rd, Pei-Tou, Taipei, Taiwan; email skye@mail.kfcc.org.tw. 2000 by American Society of Clinical Oncology. 0732-183X/00/1810-2040 2040 Journal of Clinical Oncology, Vol 18, No 10 (May), 2000: pp 2040-2045 Downloaded from jco.ascopubs.org on March 11, 2014. For personal use only. No other uses without permission. Copyright 2000 American Society of Clinical Oncology. All rights reserved. graphic information, general medical and family history, as well as specic, clinical, and treatment history; (2) an imaging review form, which recorded imaging information regarding the head and neck areas; (3) a CT form, which contained CT information and information about CT-related complications; (4) a radiotherapy form, which con- tained radiotherapy information and radiotherapy-related complica- tions; (5) a follow-up form, which was submitted every 3 to 6 months after the completion of all treatments or when tumor relapse was observed; and (6) a late-complication form, which was submitted when any late complications were observed. After the publication of the revised AJCC staging system in 1997, the head and neck images of all patients were reviewed and their staging reclassied according to the new criteria. Forty-four patients were identied as having AJCC 1997 stage I and II NPC. Twelve patients (11 in stage I, one in stage II) had been treated with radiotherapy alone, and 32 patients (all in stage II) with CCRT followed by adjuvant CT. Pretreatment evaluations included a complete history; physical examination; beroptic endoscopic examination of the nasopharynx, oropharynx, and larynx; magnetic resonance imaging (MRI) and/or computed tomography of the head and neck (37 patients were evaluated by MRI, and seven by computed tomography); chest radiographs; radionuclide bone scan; ultrasonography of the liver; complete blood counts; and serum chemistry measurements. Patients who were eligible for CCRT had to have a pretreatment peripheral absolute granulocyte count of 2,000/L, platelet count of 100,000/L, and a creatinine concentration less than 1.5 mg/dL. Informed consent was obtained from patients treated with CCRT in accordance with the procedures of the Institutional Review Board of the Koo Foundation Sun Yat-Sen Cancer Center. Radiotherapy Details of the radiotherapy technique have previously been report- ed. 9,10 In brief, all patients had computed tomography of the head and neck region for planning performed while they were in the treatment position. This was used to delineate treatment volumes, which included the primary tumor site and the neck nodes up to the clavicle. Computed tomographyassisted radiation treatment planning was obtained before the initiation of radiotherapy. An appropriate isodose line (usually 96% to 98% of the central axis dose) was chosen to cover all gross tumor volume shown on the computed tomographyassisted treatment-plan- ning charts. The nasopharynx and upper neck were treated with 6-MV photons through bilateral opposed elds and reserved 18-MV photons for an off-cord boost and 9-MV electrons for a postneck boost. A separate anterior low-neck eld with spinal-cord shielding was used for the low neck and supraclavicular fossa. Radiotherapy was administrated ve times a week at 2 Gy per day up to a total dose of 70 Gy. The spinal cord was excluded from photon elds after 44 Gy were administered. The accumulated dose given to the primary tumor and involved neck lymph nodes was 70 Gy and was 50 to 60 Gy to uninvolved areas. There was a 1-week break after 44 Gy had been delivered in the CCRT group. Chemotherapy Chemotherapy consisted of cis-diamine-dichloroplatinum (CDDP) and uorouracil (5-FU). A CDDP 100 mg/m 2 bolus injection was delivered on day 1, and FU 1,000 mg/m 2 was administered by 24-hour continuous infusion daily on days 1 through 5 for 5 days. Sixty percent of the drug doses were given to the patients when CT was administered concomitantly with radiation. Four courses of chemotherapy were delivered: two simultaneously with radiotherapy on weeks 1 and 6 and an additional two courses monthly after the completion of radiotherapy. Follow-Up All patients were evaluated for disease control, complications, and survival by a multidisciplinary team of physicians at 2-month intervals for the rst 2 years, at 3- to 6-month intervals between the third and fth years, and at 1-year intervals thereafter. Follow-up examination of the primary tumor was assessed by beroptic endoscopy and MRI 3 months after the completion of radiotherapy. Fiberoptic endoscopy was subsequently performed on every return visit. All patients underwent MRI every 6 months for the rst 2 years and annually between the third and fth years. Blood chemistry panels, whole-body bone scans, and liver sonography were performed every 6 months in the rst 3 years and every 12 months thereafter. Follow-up data were obtained as of June 1999. For patients with recurring disease, the restaging work-up was performed in the same manner as that in the initial evaluation. Statistical Methods The duration of the locoregional control, disease-free survival, and overall survival were calculated from the rst day of treatment until the day that tumor recurrence or patient death was observed. Survival and recurrence estimates were calculated according to the methods of Kaplan and Meier. 11 RESULTS The patient characteristics in the radiotherapy and CCRT groups are listed in Table 1. There were no signicant differences in male-to-female ratio and age distribution in the two groups of patients. The series presented here did not Table 1. Patient Characteristics in Early-Stage NPC Characteristic Radiotherapy CCRT P No. of Patients % No. of Patients % Sex Male 8 67 21 66 .95 Female 4 33 11 34 Age 30 years 0 2 6 .68 31-40 years 5 42 9 28 41-50 years 4 33 8 25 51-60 years 1 8 7 22 60 years 2 17 6 19 Histology WHO type 2 3 25 9 28 .84 WHO type 3 9 75 23 72 Palpable neck lymph node 1 8 21 66 .001 Stage I 11 92 0 .001 IIA (T2aN0) 0 2 6 IIB 1 8 30 94 T1N1 0 12 T2aN1 0 9 T2bN0 0 1 T2bN1 1 8 Abbreviation: WHO, World Health Organization. 2041 CCRT FOR EARLY-STAGE NPC Downloaded from jco.ascopubs.org on March 11, 2014. For personal use only. No other uses without permission. Copyright 2000 American Society of Clinical Oncology. All rights reserved. include patients with WHO type 1 histologies; WHO type 2 and 3 histologies were almost equally distributed in both groups (three of nine v nine of 23, respectively; P .84). However, the group with radiotherapy alone, compared with the CCRT group, consisted of fewer patients with palpable neck lymph nodes (one of 12 v 21 of 32, respectively; P .001) and more patients having AJCC 1997 stage I disease (11 of 12 v none of 32; P .001). By the end of June 1999, with a minimum follow-up period of 18 months and a median follow-up interval of 42 months (radiotherapy group: median, 34 months, range, 19 to 88 months; CCRT group: median, 44 months, range, 18 to 102 months), one of 12 patients in the radiotherapy group who had T1N0 disease and no patients in the CCRT group experienced local disease recurrence. In the CCRT group, two of 32 patients developed distant metastases; both patients were classied as having T2bN1M0 disease. There were no distant metastases in the radiotherapy group. The single patient who experienced local recurrence in the radiotherapy group underwent salvage surgery and re- mained disease-free for 34 months after surgery. Two patients had persistent disease after receiving 70 Gy of radiation (one in the radiotherapy group, the other in the CCRT group); the radiation doses were increased in these two patients to a total of 90 Gy and 82 Gy, respectively. Both patients were not considered to have locoregional recurrence. They remained disease-free for 19 and 43 months, respectively, after radiotherapy. The locoregional control rate calculated by log-rank test was better in the CCRT group than in the radiotherapy group, although statistic signicance was not reached (100% v 91.7%, respectively; P .10). At 3 years, the disease-free survival rate was 91.7% (95% condence interval [CI], 76.0% to 100%) in the radiotherapy group and 96.9% (95% CI, 90.8% to 100%; P .66) in the CCRT group (Figs 1A and 1B). The overall survival rates at 3 years in both groups were 100%. Patient compliance in the CCRT group was excellent. The radiation interval ranged from 48 to 65 days; 20 (63%) of 32 patients completed radiotherapy within 8 weeks and 29 (91%) of 32 completed radiotherapy within 9 weeks. Twenty-eight (88%) of 32 patients received four courses of CT, and 31 (97%) of 32 received at least two cycles of concurrent CT. All patients were evaluated for toxicity from radiotherapy and CT according to the National Cancer Institute Common Toxicity Criteria. Acute toxicity of CCRT and postradiation CT were reversible and tolerated by the patients (Table 2). Mucositis, pharyngitis, and nausea and vomiting were the major side effects during CCRT. Grade 3 mucositis and pharyngitis occurred in 62.5% and 15.6% of patients, respectively. Two patients (6%) experienced grade 4 toxic- ity; both of them developed severe and persistent vomiting and required parenteral support. No patient experienced weight loss greater than grade 2 because 25% (eight of 32) of our CCRT patients had feeding tubes inserted for nutritional support. In contrast, 8% (one of 12) of patients in the radiotherapy group were tube-fed. During postradiation CT, grade 3 mucositis and nausea and vomiting occurred at a much lower rate, in 17.2% and 10.3% of patients, respectively. One patient (3%) experienced grade 4 infec- tion and required hospitalization for infection control. DISCUSSION The 44 stage I and II patients in the series presented here had had excellent locoregional disease control, disease-free survival, and overall survival after radiotherapy alone or CCRT. Of these early-stage patients, those in stage II who had larger tumor volumes had a 3-year locoregional control rate of 100% and a disease-free survival rate of 96.9% after CCRT and adjuvant CT. However, patients who had smaller tumor loads (primarily the AJCC 1997 stage I patients) treated with radiotherapy alone had 3-year locoregional control and a disease-free survival rate of 91.7% (Figs 1A and 1B). Patients with NPC in AJCC 1997 stage I are usually treated with radiotherapy alone. Their 5-year survival rates are approximately 85% to 100%. 2,7 Patients with AJCC 1997 stage II disease who are treated with radiotherapy alone have had an approximately 5-year survival rate of 55% to 65%. 2,3 Similar survival results were observed on the basis of Hos classication. Sham and Choy 4 reported that in 759 patients treated in the Queen Mary Hospital in Hong Kong, the actuarial survival rates at 5 years for patients with stage I and II diseases (similar to AJCC 1997 stage I and II disease) were 80.8% and 71.5%, respectively. The series presented here demonstrated that patients who had AJCC 1997 stage II disease treated with CCRT had an equal or better survival when compared with the results of AJCC 1997 stage I patients treated with radiotherapy alone as reported in the literature. The treatment result also seemed to be much better than patients in AJCC 1997 stage II treated with radiotherapy alone, as previously reported by the investigators cited above. 2-4,7 The major dissimilarities between our study and the series cited above are that their studies preceded our study by a decade, and the image evaluation before treatment (computed tomography versus MRI) and the treatment modality (radiotherapy alone versus CCRT) are different. Image evaluation before treatment by MRI may result in 2042 CHENG ET AL Downloaded from jco.ascopubs.org on March 11, 2014. For personal use only. No other uses without permission. Copyright 2000 American Society of Clinical Oncology. All rights reserved. patients being moved from an early-stage classication to a more advanced stage. Therefore, our data demonstrate that either stage II disease detected by MRI has an outcome equally as good as stage I disease or that CCRT produces an outcome for stage II disease equivalent to stage I disease treated by radiotherapy alone, or both. In view of the fact that more patients in the CCRT group had clinically palpable lymph nodes (Table 1), which is not related with staging migration by MRI, the impact of CCRT on the survival benets of stage II patients cannot be dismissed. The survival advantage of the CCRT group in the series presented here is primarily attributed to excellent locore- gional control and a far lower incidence of distant metasta- ses. We demonstrated equal or better locoregional control rate in stage II (AJCC 1997) NPC treated with CCRT, compared with radiotherapy alone for stage I patients in our Fig 1. (A) Locoregional control in early-stage NPC treated with radiotherapy (RT) alone or concomitant radiotherapy and chemotherapy (CCRT). The 3-year locoregional control rate for the RT group is 91.7% (95% CI, 76% to 100%) and 100% for the CCRT group (P .10). (B) Disease-free survival rates in early-stage NPC treated with radiotherapy (RT) alone or concomitant radiotherapy and chemotherapy (CCRT). The 3-year disease-free survival rate for the RT group is 91.7% (95% CI, 76% to 100%) and 96.9% for the CCRT group (95% CI, 90.8% to 100%) (P .66). 2043 CCRT FOR EARLY-STAGE NPC Downloaded from jco.ascopubs.org on March 11, 2014. For personal use only. No other uses without permission. Copyright 2000 American Society of Clinical Oncology. All rights reserved. own institution, using contemporary radiation therapy facil- ities and techniques, 9,10 despite the fact that stage II patients had a greater tumor burden. We believe that the excellent locoregional control in our series is attributable to a more precise delineation of the tumor volume by MRI, 12-14 individualized radiation treat- ment planning, and concomitant CT. 9,10 The improvement of locoregional control rate due to stage migration by MRI is less likely because, using same diagnostic and treatment modalities, we have previously reported an excellent 3-year primary tumor control rate of 92% for AJCC 1992 T4 patients. 15 More favorable histology types, such as nonke- ratinizing carcinoma and poorly differentiated carcinoma, are probably another reason for the improvement of locore- gional control. These histology types are known to have greater radiosensitivity and, hence, better local control when compared with well-differentiated squamous histology. 16 Computed tomographyassisted treatment planning was used routinely in the series presented here; its benet in the locoregional control of NPC has been reported elsewhere. 10 We chose an appropriate isodose line (usually 96% to 98% of the central axis dose) to cover all gross tumor volume shown on the computed tomographyassisted treatment planning charts. The relationship between 2% to 4% dose escalation and the dramatic change of locoregional control is unknown at present. We are now performing an analysis of the relationship between tumor-dose nonhomogeneity and local control in our institution; the results will be reported soon. Distant metastases in early-stage NPC are not common. Geara et al 17 reported that the risk of distant metastases for patients with N0-N1 or N2 (similar as AJCC 1997 N1) classication was 11% to 13% and 37%, respectively, in a long-term follow-up. With T1-T2 and N0 populations, the risk of distant metastases will probably be less than 10%. Therefore, postradiation adjuvant CT in this subset of patients may not be necessary. However, for patients with AJCC 1997 T1-T2 and N1 disease, whether adjuvant CT after radiotherapy is benecial warrants further evaluation. The study of the CCRT group presented here primarily included T2N1 patients and included more patients with WHO type 3 histologies; the distant metastasis rate at 3 years was only 3.2%. In a different series, by Teo et al, 18 in which patients were evaluated by computed tomography and treated with radiotherapy alone, the 3-year distant metastasis rate in T2aN0 patients was 4% and in T2bN0 patients was 22%. Our series involved cases with more advanced disease (more T2aN1 and T2bN1 patients; Table 1) but a far lower incidence of distant metastases. The primary differences between the Teo et al study and our study are that we used MRI evaluations before treatment and a combination of radiotherapy and concomitant CT. The study presented here also showed a good compliance of our patients to the CCRT and adjuvant CT. The inter- group study by Al-Sarraf et al 8 revealed that only 55% of patients completed the combined modality treatment as planned. Our data revealed that 88% of patients completed CCRT as planned. Good compliance to CCRT was attrib- uted to the immediate intervention of nasogastric tube- feeding when patients developed 5% weight loss or grade III mucositis. 15 Our concomitant treatment is better toler- ated by patients because we administered two cycles of Table 2. Toxicity of Concurrent Radiotherapy Plus Chemotherapy and Postradiation Chemotherapy Toxicity Toxicity Grade* Grade III or Higher Toxicity in the Entire Course CCRT (n 32) Postradiation Chemotherapy (n 29) I II III IV I II III IV Nausea 38 53 6 31 45 14 19 Vomiting 31 38 9 6 21 21 14 25 Diarrhea 19 6 24 0 Stomatitis/mucositis 13 25 63 17 24 17 66 Pharyngitis 31 53 16 16 Weight loss 34 16 0 Leukopenia 41 25 31 38 7 6 Hemoglobin 44 6 3 52 3 3 6 Platelet 13 6 13 3 3 3 Creatinine 6 3 0 Infection 13 14 3 0 3 3 Maximum grade of any toxicity 3 31 59 6 10 59 24 3 *National Cancer Institute toxicity criteria. Percentage of toxicity. Weight loss was evaluated by Radiation Therapy Oncology Group criteria; eight (25%) of 32 patients had feeding tubes inserted. Three patients did not undergo postradiation chemotherapy; their creatinine data are not available. 2044 CHENG ET AL Downloaded from jco.ascopubs.org on March 11, 2014. For personal use only. No other uses without permission. Copyright 2000 American Society of Clinical Oncology. All rights reserved. chemotherapy with CDDP and FU at a 60% dose reduction during radiotherapy and two additional courses of CDDP and FU in full doses after radiotherapy. Moreover, we routinely allowed patients to have a 1-week break during radiotherapy treatment. Still, our CCRT patients experi- enced more severe mucositis and vomiting than did patients undergoing radiotherapy alone (data not shown), and the tube-feeding rate in the CCRT group was higher than in the radiotherapy group (eight of 32 v one of 12). The intergroup study concluded that CCRT is superior to radiotherapy alone in patients with AJCC1992 stage III and IV disease. However, they only included 13 patients with stage III disease (equal to AJCC 1997 stage II) in their study popula- tion. 8 As such, a conclusion that CCRT was better than radiotherapy alone in this subset of patients seemed weak. Our data presented here does offer additional support to the above conclusion that patients with AJCC 1992 stage III (now AJCC 1997 stage II) can achieve a more favorable outcome with CCRT. In summary, excellent locoregional control, fewer distant metastases, and excellent survival have been obtained in patients with AJCC 1997 stage II NPC who were evaluated by MRI of the head and neck and who were treated with CCRT. AJCC 1997 stage II patients, especially those with T1N1, T2aN0, and T2aN1 classications, deserve to be reviewed in the future as to whether this subset of patients ought to remain in stage II or be reclassied to a lesser stage. The benet of CCRT, compared with radiotherapy alone, in early-stage NPC awaits conrmation by a prospec- tively randomized trial. ACKNOWLEDGMENT The authors thank Yen-Chun Lin, Szu-Yun Sharon Leu, Yueh-Yun Yu, Yi-Wen Chang, and Cheng-Fang Horng in the Clinical Protocol Ofce for their thoughtful assistance with data collection, data entry, data quality control, and outcome analysis. REFERENCES 1. Fleming ID, Cooper JS, Henson DE, et al (eds): AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 31-39 2. Ozyar E, Yildiz F, Akyol FH, et al: Comparison of AJCC 1988 and 1997 classications for nasopharyngeal carcinoma: American Joint Committee on Cancer. Int J Radiat Oncol Biol Phys 44:1079-1087, 1999 3. Cooper JS, Cohen R, Stevens RE: A comparison of staging systems for nasopharyngeal carcinoma. Cancer 83:213-219, 1998 4. Sham JS, Choy D: Prognostic factors of nasopharyngeal carci- noma: A review of 759 patients. Br J Radiol 63:51-58, 1990 5. Teo PM, Chan AT, Lee WY, et al: Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by ad- junctive chemotherapy. Int J Radiat Oncol Biol Phys 43:261-271, 1999 6. Beahrs OH, Henson DE, Hutter RVP, et al (eds): Manual for the Staging of Cancer. Philadelphia, PA, Lippincott-Raven, 1992, pp 33-38 7. Chang JT, See LC, Tang SG, et al: The role of brachytherapy in early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 36:1019-1024, 1996 8. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III Randomized Intergroup Study 0099. J Clin Oncol 16:1310- 1317, 1998 9. Cheng SH, Liu TW, Jian JJ, et al: Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cancer J Sci Am 3:100-106, 1997 10. Jian JM, Cheng SH, Prosnitz LR, et al: T classication and clivus margin as risk factors for determining locoregional control by radiotherapy of nasopharyngeal carcinoma. Cancer 82:261-267, 1998 11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958 12. Chong VF, Fan YF, Khoo JB: Nasopharyngeal carcinoma with intracranial spread: CT and MR characteristics. J Comput Assist Tomogr 20:563-569, 1996 13. Chong VF, Fan YF, Khoo JB: MRI features of cervical nodal necrosis in metastatic disease. Clin Radiol 51:103-109, 1996 14. Chong VF, Fan YF: Skull base erosion in nasopharyngeal carcinoma: Detection by CT and MRI. Clin Radiol 51:625-631, 1996 15. Cheng SH, Jian JJ, Tsai SY, et al: Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carci- noma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 41:755-762, 1998 16. Sanguineti G, Geara FB, Garden AS, et al: Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control. Int J Radiat Oncol Biol Phys 37:985-996, 1997 17. Geara FB, Sanguineti G, Tucker SL, et al: Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of distant metastasis and survival. Radiother Oncol 43:53-61, 1997 18. Teo P, Yu P, Lee WY, et al: Signicant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carci- noma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 36:291-304, 1996 2045 CCRT FOR EARLY-STAGE NPC Downloaded from jco.ascopubs.org on March 11, 2014. For personal use only. No other uses without permission. Copyright 2000 American Society of Clinical Oncology. All rights reserved.
(Methods in Molecular Biology 823) Stacy M. Cowherd (Auth.), Virginia Espina, Lance A. Liotta (Eds.) - Molecular Profiling - Methods and Protocols (2012, Humana Press)